Drug Shortage Report for TEVA-NAPROXEN
| Report ID | 177529 |
| Drug Identification Number | 00589861 |
| Brand name | TEVA-NAPROXEN |
| Common or Proper name | TEVA-NAPROXEN 500MG TAB |
| Company Name | TEVA CANADA LIMITED |
| Market Status | MARKETED |
| Active Ingredient(s) | NAPROXEN |
| Strength(s) | 500MG |
| Dosage form(s) | TABLET |
| Route of administration | ORAL ORAL |
| Packaging size | 100 |
| ATC code | M01AE |
| ATC description | ANTIINFLAMMATORY/ANTIRHEUMATIC PROD.,NON-STEROIDS |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | |
| Actual start date | 2022-12-07 |
| Estimated end date | 2023-01-20 |
| Actual end date | 2023-01-17 |
| Shortage status | Resolved |
| Updated date | 2023-01-19 |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v6 | 2023-01-19 | French | Compare |
| v5 | 2023-01-19 | English | Compare |
| v4 | 2023-01-12 | French | Compare |
| v3 | 2023-01-12 | English | Compare |
| v2 | 2022-12-08 | French | Compare |
| v1 | 2022-12-08 | English | Compare |
Showing 1 to 6 of 6